Publications

A Phase 1/2 study of the WEE1 inhibitor Debio 0123 in combination with temozolomide +/– radiotherapy in adults with recurrent…

The Multilink(TM) Linker is a promising approach to improve efficacy and safety of ADC’s

Evaluation of the microbiota-sparing properties of the anti-staphylococcal antibiotic afabicin

First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CAIX-expressing tumors

Debio 0123-101, a phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors: safety, pharmacokinetic, and…

Debio 0123 is a selective WEE1 inhibitor that effectively penetrates the brain and demonstrates anti-tumor activity in preclinical models of…

Pharmacokinetic-pharmacodynamic modelling of afabicin in vitro activity against Staphylococcus aureus

Debio 0123, A Selective WEE1 Inhibitor in Clinical Development for Patients with Solid Tumors

Safety assessment of DPI-4452, a cyclic peptide targeting Carbonic Anhydrase IX